PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

Kohlberg is a leading private equity firm headquartered in Mount Kisco, N.Y. with over 30 years of successful experience partnering with management and companies like PCI Pharma Services.

Kohlberg & Co has come out on top in one of healthcare’s most anticipated processes this summer, striking a $3-billion-plus deal for PCI Pharma Services, PE Hub has learned.. Swiss private ...

DUBAI, Aug 24 (Reuters) - Private equity firm Kohlberg & Company and Abu Dhabi state investor Mubadala have agreed to take a controlling stake in PCI Pharma Services, a U.S. pharmaceutical ...

The buyout firm is in discussions with PCI's backers — Kohlberg & Co, Mubadala Investment Co and Partners Group Holding AG — about a deal for a majority stake of the Philadelphia-based drug ...

Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter.

The buyout firm is in discussions with PCI's backers — Kohlberg & Co, Mubadala Investment Co and Partners Group Holding AG — about a deal for a majority stake of the Philadelphia-based drug ...